Evidence map›Paper›PMID 39703787›Full record

ArticleOpen forum infectious diseases2024

Utility of

Pei-Ju Chuang, Wei-Cheng Lan, Mei-Fang Cheng, Chun-Kai Huang, Tzu-Chan Hong, Chi-Ying Lin, Yu-Shan Huang, Pao-Yu Chen, Un-In Wu, Jann-Tay Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Pathogens (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Pei-Ju ChuangDepartment of Nuclear Medicine, National Taiwan University Hospital, Yunlin Branch, Yunlin, Taiwan.ORCID https://orcid.org/0000-0002-3613-2756
Wei-Cheng LanDepartment of Nuclear Medicine, National Taiwan University Hospital, Yunlin Branch, Yunlin, Taiwan.
Mei-Fang ChengDepartment of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.ORCID https://orcid.org/0000-0002-9359-0606
Chun-Kai HuangDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Tzu-Chan HongDepartment of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
Chi-Ying LinDepartment of Internal Medicine, National Taiwan University Hospital, Yunlin Branch, Yunlin, Taiwan.
Yu-Shan HuangDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.ORCID https://orcid.org/0000-0002-9047-5709
Pao-Yu ChenDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Un-In WuDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Jann-Tay WangDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Wang-Huei ShengDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Yee-Chun ChenDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.ORCID https://orcid.org/0000-0002-1816-9010
Shan-Chwen ChangDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.ORCID https://orcid.org/0000-0001-6505-4139

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Managing disseminated nontuberculous mycobacterial (NTM) infection in patients with neutralizing anti-interferon-γ autoantibodies (AIGAs) poses substantial challenges due to the lack of established treatment guidance and predictive tools for clinical outcomes. In this study, we investigated the utility of Methods: We conducted a post hoc analysis of the first available 2-[ Results: Of the patients with AIGAs evaluated, 41.9% required rehospitalization within 1 year following the initial 2-[ Conclusions: 2-[

Indexed as

anti-interferon-gamma autoantibodiesfluorodeoxyglucose F18immunodeficiencynontuberculous mycobacterial infectionPET

Identifiers

PMID39703787
PMCPMC11656338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.